By Fineline Cube AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for SKYRIZI (risankizumab) for the treatment of children and adolescents aged six years and older with moderate to severe plaque psoriasis who are candidates for systemic therapy. The approval includes a new 55 mg pre-filled syringe (PFS) specifically designed to support weight-based dosing for patients weighing less than 40 kg, addressing a critical unmet need in pediatric dermatology.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Commission (EC) |
| Approval Type | Full marketing authorization |
| Product | SKYRIZI (risankizumab) – IL-23 inhibitor |
| Indication | Moderate to severe plaque psoriasis in patients ≥6 years old |
| Approval Date | 23 Jun 2026 |
| New Formulation | 55 mg pre-filled syringe for weight-based dosing (<40 kg patients) |
| Global Status | First IL-23 inhibitor approved for pediatric psoriasis in EU; previously approved for adults in US and EU for psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis |
Drug Profile & Mechanism of Action
- Compound: Risankizumab – selective interleukin-23 (IL-23) inhibitor
- Mechanism: Targets the p19 subunit of IL-23, a key cytokine driving inflammatory pathways in psoriasis
- Therapeutic Innovation: First IL-23 inhibitor authorized for pediatric use in the EU, extending AbbVie’s leadership in biologic psoriasis treatments
- Dosing Flexibility: New 55 mg PFS enables precise weight-based dosing for smaller pediatric patients, improving treatment accuracy and safety
- Administration: Subcutaneous injection with established dosing regimens optimized for pediatric populations
Clinical Evidence – OptIMMize Pediatric Program
| Study Component | Population | Design | Key Outcomes |
|---|---|---|---|
| OptIMMize-1 Lead-in Cohorts | 137 pediatric patients | Two cohorts: randomized assessor-blinded (12-<18 years) + single-arm open-label (6-<12 years) | Met primary endpoints for efficacy and pharmacokinetics |
| OptIMMize-2 Extension Study (NCT04862286) | Long-term follow-up | Open-label extension | Confirmed sustained efficacy and long-term safety |
| Safety Profile | n=137 pediatric patients | Comprehensive safety monitoring | Consistent with adult data; no new safety signals identified |
The pediatric approval was supported by robust clinical data demonstrating efficacy comparable to adult populations with a favorable safety profile that mirrors the established adult experience.
Market Impact & Strategic Outlook
- Pediatric Psoriasis Landscape: Approximately 40,000 children in the EU suffer from moderate to severe plaque psoriasis, with limited biologic treatment options previously available
- Commercial Opportunity: Pediatric indication expands SKYRIZI’s addressable market by an estimated €300-400 million annually across major European markets
- Competitive Positioning: First-mover advantage in the pediatric IL-23 inhibitor segment, ahead of competing mechanisms including IL-17 and TNF inhibitors
- Franchise Expansion: Strengthens AbbVie’s immunology portfolio leadership while establishing early treatment paradigms that may drive long-term patient retention into adulthood
- Healthcare System Benefits: Weight-based dosing optimization reduces waste and improves cost-effectiveness for healthcare systems managing chronic pediatric conditions
Forward-Looking Statements
This brief contains forward-looking statements regarding commercial performance, market adoption, and regulatory developments. Actual results may differ due to risks including competitive dynamics, pricing negotiations, reimbursement decisions, and post-marketing safety surveillance requirements.-Fineline Info & Tech